Christopher Zarembinski, MD
Pain Medicine · West Hollywood, CANPI 1811984347
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,496 of the $3,244 with a category attached, or 77.0%. Stratus Medical, LLC accounts for 67.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,459 and has fallen 89.1% since, to $159 in 2025.
Across 27 payments — averaging $120.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stratus Medical, LLC$2K
- Nevro Corp.$179
- Johnson & Johnson$166
- Avanos Medical$155
- SPR Therapeutics, Inc$154
- Vertos Medical, Inc.$151
- plus $252 from 2 others
What the payments were for
- Travel & lodging$74723%
- Food & beverage$2,49677%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stratus Medical, LLC | 14 | $2,187 |
| Nevro Corp. | 3 | $179 |
| Johnson & Johnson | 3 | $166 |
| Avanos Medical | 1 | $155 |
| SPR Therapeutics, Inc | 2 | $154 |
| Vertos Medical, Inc. | 2 | $151 |
| Nalu Medical, Inc. | 1 | $143 |
| Pacira Therapeutics, Inc. | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nimbus$1,709
- GENERATOR$155
- Nalu Neurostimulation System$143
- PEAK$117
- Zilretta$109
How this compares
$3,244 in reported general payments places this provider in the 60th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $1,655 |
| Tramadol Hcl ErTramadol Hcl | 22 | $1,049 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $558 |
| Celecoxib | 22 | $536 |
| Oxycodone Hcl | 29 | $444 |
| Gabapentin | 32 | $342 |
| Methocarbamol | 22 | $252 |
| Tizanidine Hcl | 40 | $214 |
| Tramadol Hcl | 31 | $66 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in West Hollywood
- Howard RosnerWest Hollywood$79K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.